Ya.V. Vilenskyi

Ya.V. Vilenskyi

Auto-generated profile, based on publicly available information

Ya.V. Vilenskyi

Dnipro State Medical University, Dnipro, Ukraine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2024 in CHILD`S HEALTH
Verified
Journal Article
Open access
PDF file
OSO.V. Shvaratska
O.V. Shvaratska
MKM.V. Kalichevska
M.V. Kalichevska
OKO.V. Klymenko
O.V. Klymenko
OTO.M. Taran
O.M. Taran
YVY.V. Vilenskyi
Y.V. Vilenskyi
TMT.K. Mavropulo
T.K. Mavropulo
Systemic autoinflammatory diseases (SAIDs) are a group of inherited monogenic diseases characterized by dysregulated innate immunity leading to excessive activation of inflammatory pathways. Recently, some molecular mechanisms typical for autoinflammation have also been recognized in the pathogenesis of several autoimmune and immunodeficiency states. This scientific review aimed to systematize current ideas about autoinflammatory diseases to increase medical professionals’ awareness regarding the issue, which is significantly lower than that of other categories of immune dysfunction. We performed a focused search over the Web of Science, Scopus, PubMed Central®, Google Scholar databases over the past 10 years using the keywords “autoinflammatory diseases”, “autoinflammatory syndromes”, “autoinflammation”. The review reflects the historical evolution of scientific views on the immunopathogenesis of autoinflammation since the introduction of the concept in 1999: from the interleukin (IL)-1-centered paradigm to recognition of the significant role of other signaling pathways. Further, we discuss the place of autoinflammation in the spectrum of immunological disorders and present current scientific data on the immunobiological basis of autoinflammation. In particular, we review how the innate immune system triggers inflammation within the inflammasome, interferon and nuclear factor kappa B ­(NF-κB) signaling pathways, highlighting the role of intracellular sensor proteins, inflammasomes, gasdermin D, IL-1β, IL-18 and IL-36, ­NF-κB, tumor necrosis factor, type 1 interferons, and others. Based on the underlying molecular pathogenesis, the following classification categories of SAIDs have been suggested recently: inflammasomopathies and other enhanced IL-1 signaling syndromes, interferonopathies, relopathies, protein misfolding diseases/endoplasmic reticulum stress syndromes, other cytokine-signaling disorders and complementopathies. The review also discusses diagnostic challen­ges and presents current scientific recommendations for the diagnosis of SAIDs, highlighting the distinguishing features of the classic autoinflammatory disorders and the existing potential of diagnostic tests.

22 April 2025 in CHILD`S HEALTH
Verified
Journal Article
Open access
PDF file
OSO.V. Shvaratska
O.V. Shvaratska
TBT.A. Bordii
T.A. Bordii
MKM.V. Kalichevska
M.V. Kalichevska
OKO.V. Klymenko
O.V. Klymenko
OTO.M. Taran
O.M. Taran
TMT.K. Mavropulo
T.K. Mavropulo
Inflammasomopathies and other enhanced interleukin (IL)-1 signaling syndromes represent a significant cluster of systemic autoinflammatory diseases (SAIDs) which are monogenic disorders characterized by episodic spontaneous multisystemic inflammation mediated by innate immunity and resulting mainly from inappropriate activation of antigen-independent inflammatory mechanisms without production of autoantibodies. Autoinflammation is currently considered a distinct category of immune dysfunction along with autoimmunity/allergy and immunodeficiency. This scientific review is the third in a series of publications aimed at raising awareness among healthcare professionals regarding the diagnosis and management of SAIDs in children. The review highlights the immunobiological features of inflammasomes containing nucleotide-binding domain, leucine-rich repeat-containing proteins (NLRs). It also presents the clinical and pathogenetic features of the currently genetically defined NLRP3-, NLRP12-, NLRP1- and NLRC4-associated inflammasomopathies. The paper also discusses the potential of biologic-targeted therapies for inflammasomopathies which are now considered a key trend in the treatment of SAIDs and based on the molecular immunopathogenesis of the disease. Furthermore, we summarized the current experience of using available biological agents in the treatment of specific inflammasomopathies, namely agents blocking the effects of IL-1, IL-6, IL-17, IL-12/23, interferon-gamma, and tumor necrosis factor. Data were collected through a focused search over the Web of Science, Scopus, PubMed Central®, Google Scholar databases for the past 10 years using the keywords “autoinflammatory diseases”, “autoinflammation”, “inflammasomopathies”, “NLRP”, “NLRC”, “biologic therapies”.

29 December 2024 in CHILD`S HEALTH
Verified
Journal Article
Open access
PDF file
OSO.V. Shvaratska
O.V. Shvaratska
TBT.A. Bordii
T.A. Bordii
KHK.K. Hodiatska
K.K. Hodiatska
MKM.V. Kalichevska
M.V. Kalichevska
OKO.V. Klymenko
O.V. Klymenko
YVYa.V. Vilenskyi
Ya.V. Vilenskyi
Systemic autoinflammatory diseases (SAIDs) are considered dysregulation disorders of the innate immune system characterized by systemic sterile inflammation independent of infection and autoreactive antibodies or antigen-specific T cells. Autoinflammation is often mediated by inflammasomes; accordingly, inflammasomopathies and other enhanced interleukin (IL) 1 signaling syndromes represent a major classification group of SAIDs. Inflammasomes differ by the type of intracellular receptor which acts as a scaffold protein for the entire complex. Specifically, pyrin is one of the main intracellular sensor proteins that can initiate the formation of inflammasomes. This scientific review is the second in a series of publications jointly aiming to increase medical professionals’ awareness of SAIDs in children. It focuses on the current scientific understanding of pyrin inflammasomopathies which represent a significant cluster of all inflammasomopathies and other enhanced IL-1 signaling syndromes. We performed a focused search over the Web of Science, Scopus, PubMed Central®, Google Scholar databases over the past 10 years using the keywords “autoinflammatory diseases”, “autoinflammation”, “inflammasomopathies”, “pyrin”. The work presents an overview of inflammasomopathies, discusses the immunobiological features of the sensor protein pyrin and pyrin inflammasomes including cellular expression and molecular mechanisms of their activation and signal limitation. The review also presents the clinical and pathogenetic characteristics of the genetically determined pyrin inflammasomopathies and other enhanced IL-1 signaling syndromes: familial Mediterranean fever; pyrin-associated autoinflammation with neutrophilic dermatosis; mevalonate kinase deficiency; PSTPIP1-associated inflammatory diseases; periodic fever, immunodeficiency and thrombocytopenia syndrome; neonatal-onset cytopenia with dyshematopoiesis, autoinflammation, rash, and hemophagocytic lymphohistiocytosis; deficiency of IL-1 receptor antagonist; deficiency of IL-36 receptor antagonist; loss of IL-1 receptor to IL-1 receptor antagonist syndrome.